ATyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
January 31, 2019 at 02:30 am IST
Share
aTyr Pharma, Inc. announced that it has expanded a successful pilot study and entered into a research collaboration with the University of Nebraska Medical Center (UNMC). Dr. Kausttubh Datta, Professor of Biochemistry and Molecular Biology at UNMC, will serve as the investigator for the research collaboration. Dr. Datta is an expert in the field of neuropilin-2 (NRP-2) biology and conducts research related to molecular mechanisms of cancer progression and metastasis. The collaboration will investigate; the role of ATYR1923 on modulating the functional properties of myeloid cells, including macrophage biology, the importance of endogenous Resokine:NRP-2 interactions in other functional properties of myeloid cells, the involvement of individual NRP-2 co-receptors/ligands on myeloid cell biology and an assessment of the impact of different anti-NRP-2 domain-specific antibodies in immunology and cancer biology.
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
ATYR PHARMA, INC. 
